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Eramah Ermiah1,3*, Fathi Abdalla2,4, Abdelbaset Buhmeida5, Entesar Larbesh6, Seppo Pyrhönen1 and Yrjö Collan2Abstract
Aims: To study the diagnosis delay and its impact on stage of disease among women with breast cancer
on Libya.
Methods: 200 women, aged 22 to 75 years with breast cancer diagnosed during 2008–2009 were interviewed about
the period from the first symptoms to the final histological diagnosis of breast cancer. This period (diagnosis time)
was categorized into 3 periods: <3 months, 3–6 months, and >6 months. If diagnosis time was longer than 3 months,
the diagnosis was considered delayed (diagnosis delay). Consultation time was the time taken to visit the general
practitioner after the first symptoms. Retrospective preclinical and clinical data were collected on a form
(questionnaire) during an interview with each patient and from medical records.
Results: The median of diagnosis time was 7.5 months. Only 30.0% of patients were diagnosed within 3 months after
symptoms. 14% of patients were diagnosed within 3–6 months and 56% within a period longer than 6 months. A
number of factors predicted diagnosis delay: Symptoms were not considered serious in 27% of patients. Alternative
therapy (therapy not associated with cancer) was applied in 13.0% of the patients. Fear and shame prevented the visit
to the doctor in 10% and 4.5% of patients, respectively. Inappropriate reassurance that the lump was benign was an
important reason for prolongation of the diagnosis time. Diagnosis delay was associated with initial breast symptom
(s) that did not include a lump
(p < 0.0001), with women who did not report monthly self examination (p < 0.0001), with old age (p = 0.004), with
illiteracy (p = 0.009), with history of benign fibrocystic disease (p = 0.029) and with women who had used oral
contraceptive pills longer than 5 years (p = 0.043). At the time of diagnosis, the clinical stage distribution was as
follows: 9.0% stage I, 25.5% stage II, 54.0% stage III and 11.5% stage IV.
Diagnosis delay was associated with bigger tumour size (p <0.0001), with positive lymph nodes (N2, N3; p < 0.0001),
with high incidence of late clinical stages (p < 0.0001), and with metastatic disease (p < 0.0001).
Conclusions: Diagnosis delay is very serious problem in Libya. Diagnosis delay was associated with complex
interactions between several factors and with advanced stages. There is a need for improving breast cancer awareness
and training of general practitioners to reduce breast cancer mortality by promoting early detection. The treatment
guidelines should pay more attention to the early phases of breast cancer. Especially, guidelines for good practices in
managing detectable of tumors are necessary.
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In Libya, breast cancer is an important health problem
among women. The incidence is 18.8 new cases per
100,000 women per year [1]. Most of the patients
present with advanced disease [1,2]. The patients are
often younger than in Europe, in line with the pattern
common in Middle East and North Africa (MENA) [3].* Correspondence: eelramah@yahoo.com
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reproduction in any medium, provided the orTo improve breast cancer care better understanding of
the predicting factors and causes for treatment delay are
important issues [4]. Small tumors are more likely to
be treated successfully [5,6]. Delayed presentation of
breast cancer is associated with advanced stage and low
survival [7-9].
Studies in developed countries reported that median
time to consultation was 14–61 days [10-12]. A delay of
more than 3 months prior to physician consultation oc-
curred in 14-53% of cases [12-15]. Low socio-economic
status, minority ethnicity and young age were associatedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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delay was also associated with older age, lighter symp-
toms, fear of to informing anyone, negative attitude to-
ward medical practitioners and fear of treatment [14].
Failures of medical practitioners to act on clinical find-
ings, and false-negative mammogram or fine needle as-
piration cytology (FNAC) were the main factors for
delay after the visit to the general practitioner [15,16].
We conducted this study to learn more about the ex-
tent and reasons behind diagnosis delay of breast cancer
in Libya.Patients and methods
The study group was two hundred Libyan female
patients with breast cancer diagnosed at the African
(presently (2012) National) Oncology Institute (NOI),
Sabratha, during the period from Jan 1, 2008 to Dec 31,
2009. During that time 419 patients were registered at
the institute. The patients were asked to be interviewed
and the collection of data was stopped after 200 inter-
views had been completed.Data collection
Preclinical data was collected on a form (questionnaire)
during the interview with each patient. Questionnaire
for assessment of diagnosis delay is shown in Table 1.
Structured face-to-face interviews were arranged either
during the first hospitalization due to breast cancer
(20%) or during follow-up in the outpatient department
(80%). 22.5% of all interviews took place within 4 weeks
after diagnosis and 77.5% within 8 weeks after diagno-
sis. The interviews were conducted by a trained phy-
sician (E.E and E.L) and required 30 to 45 minutes to
complete.
The data collection included social and demographic
data, medical and obstetric history, symptom-related
questions, and consultation-related questions. Dates of
the chronological events (first recognition of symptoms,
first consultation, referral and first hospital appoint-
ment) were included. Diagnosis time and delays were
estimated in days.
First symptoms included: lump, breast symptoms
other than lump, and symptoms not related to the
breast. The respondents were questioned about previous
use of oral contraceptives, hormone replacement therapy
or alternative therapy if these therapies were taken re-
gularly for at least one month. Complementary alterna-
tive therapy included any therapy using methods and
products not associated with conventional modern
medicine.
In order to minimize recall bias, the respondents were
reminded of events in the calendar year, such as reli-
gious and national occasions, school holidays and birthdates, to help them remember important dates relative
to their medical history.
Data regarding tumour stage relied on histopatho-
logical and clinical data including TNM stage [17] were
collected from medical records of each patient. A previ-
ous report suggests that the collection of data from
medical records is more accurate than the patient inter-
view alone [18].Diagnosis time
Diagnosis time was measured from the date of the first
symptoms to the date of final breast cancer diagnosis
based on histopathological examination (including nee-
dle biopsy or excisional biopsy) or on FNAC (fine needle
aspiration cytology). Consultation time was the time
taken to visit the general practitioner after the first
symptoms.Statistical analysis
Diagnosis time was categorized into periods: <3 month,
3–6 months, and > 6 months and we use three months
as cut-off point of delay [10,15]. Diagnosis was consid-
ered delayed if it took longer than 3 months after symp-
toms to reach the final diagnosis of breast cancer
(diagnosis delay).
Socio-demographic characteristics, as potential deter-
minants of diagnosis delay, included age, education, and
employment status. Health characteristics, evaluated as
potentially affecting the duration of diagnostic time,
included menopausal status, use of oral contraceptives;
breast self examination, history of fibrocystic disease,
and family history of breast cancer.
Data were analyzed using SPSS for Windows (version
17, SPSS, Inc., Chicago, USA). The Chi-square test, with
likelihood ratio (LR), or Fisher’s exact test was used to
assess the significance of the association between poten-
tial predicator factors and diagnosis delay, and to iden-
tify independent determinants of diagnosis delay of 3 to
6 months and more than 6 months versus less than
3 month. Additionally the association between diagnosis
delay and clinical stage was examined for all patients. In
all tests, the values p <0.05 were regarded statistically
significant.Ethical consideration
This study is a part of the breast cancer studies, which
got permission from the local ethical committee of the
African Oncology Institute (since 2012 the National On-
cology Institute) Sabratha, Libya. All respondents in this
study gave oral consent, after the character of the inter-
view was explained to them. No patients refused the
interview.
Table 1 Questionnaire for assessment of diagnosis delay
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Duration between first symptoms and
first visit to the doctor
Duration between the first visit to the
doctor and histopathological or cytological
diagnosis
Table 1 Questionnaire for assessment of diagnosis delay
in women with breast cancer in Libya (Continued)
Duration between the first symptoms and
histopathological or cytological diagnosis.
Clinical staging at time of the diagnosis
(from the patients files)
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Study population
The characteristics of the study population (n = 200) are
shown in Table 2. The mean age of women was
45.4 years (range 22–75 years). Sixty-two percent of
patients (n = 124) were literate. Seventy- nine percent of
patients (n = 158) were married, multi-parous, and had
fed their babies. 24.5% of patients (n = 49) had taken oral
contraceptive pills, 26% did not have any children, and
36.5% were post-menopausal. Only 9% had a family his-
tory of breast cancer, 9.5% had a history of benign breast
disease. In this study, 136 (68%) patients with breast car-
cinoma noted a lump or lumps as an accidental finding,
while 4 (2%) patients detected lump(s) during self
examination.
Family physician noted a lump in 1 case and referred
the patient to a proper health care facility. Other symp-
toms of the breast such as skin changes, nipple discharge
or bleeding were reported less frequently (29%). Sys-
temic involvements as the first symptom occurred in 6
(3%) patients.
Diagnosis delay
Diagnosis time is shown on Figure 1.
The median of diagnosis time was 7.5 months,
25 months as the maximum. 30% (n = 60) of patients
were diagnosed within 3 months after detecting symp-
toms. 14% (n = 28) of patients were diagnosed within
3–6 months and 56% (n = 112) within a period longer
than 6 months.
The median of consultation time was 4 months,
24 months as the maximum. 44.5% (n = 89) of patients
had a medical consultation within one months after
detecting symptoms, while 15.5% (n = 31) had visited the
doctor within 1–6 months after symptoms. 40% (n = 80)
of patients had consultation later than 6 months after
first symptoms (Figure 2).
The majority of patients (84.5%; n = 169) were diag-
nosed within one month after the visit to the general
practitioners. 4.5% of patients (n = 9) were diagnosed
from 1 to 6 months after the first visit to the doctor, 22
(11.0%) patients had waited for more than 6 months for
the final diagnosis after the first medical consultation.
Clinical staging at time of diagnosis
At time of diagnosis, the clinical stage distribution was
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Figure 1 Diagnosis time (from first symptoms) among 200
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Figure 2 Consultation time (from first symptoms) among 200
Libyan breast cancer patients (2008–2009). Consultation time
(months).







Age (years) <50 133 66.5
≥50 67 33.5
Education Literate 124 62.0
Illiterate 76 38.0
Occupation House wife 111 55.5
Employed 89 44.5
Marital status Married 158 79.0
Single 42 21.0
Medical history of the patients
Menopausal status Pre-menopausal 127 63.5
Post-menopausal 73 36.5
Breast feeding Yes 133 89.0
No 16 11.0
Oral contraceptive Yes <5 years 35 17.5












Clinical presentations of the patients
Symptoms Lump 136 68.0
Nipple discharge 27 13.5
Skin changes 31 15.5
Systemic 6 3.0
Symptoms Lump 136 68.0
Others 64 32.0
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Table 3.
Diagnosis delay and associated factors
A number of factors predicted diagnosis delay: Symp-
toms were not considered serious in 54 (27%) patients.
Alternative therapy was applied in 13.0% of the patients.
Fear and shame prevented the visit to the doctor in 10%
and 4.5%, respectively, of the patients. 31 patients
(15.5%) were inappropriately reassured after first medical
visit that the lump was benign.
Initial breast symptom(s) without a lump was strongly
associated with diagnosis delay (p <0.0001). Diagnosisdelay tended to be higher among women who did not
report monthly breast self examination (p < 0.0001). Ol-
der women waited longer than younger women before
presenting their symptoms to a physician (p = 0.004).
Additionally a significantly higher risk of delay was
among illiterate (p = 0.009), among patients with a his-
tory of fibrocystic disease (p = 0.029) and among women
who had used oral contraceptive pills longer than 5 years
Table 3 Clinical staging and TNM classification at the
diagnosis in 200 Libyan breast cancer patients 2008-2009






Stage 1 18 9.0
Stage 2 51 25.5
Stage 3 108 54.0










T T 1 25 12.5
T 2 54 27.0
T 3 78 39.0
T 4 43 21.5
N N 0 50 25.0
N 1 76 38.0
N 2 58 29.0
N 3 16 8.0
M M 0 177 88.5
M 1 23 11.5
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shown in Table 4.
Association between diagnosis delay and clinical staging
Late clinical stage of breast cancer was found in 65.5%
of all patients (Table 3) and it tended to be more frequent
among women with diagnosis delay >6 months (89.3%)
than among women who had diagnosed < 3 months after
onset of symptoms (23%; p < 0.0001).
Diagnosis delay was significantly associated with large
tumour size (T3 and T4; p < 0.0001) and with positive
lymph nodes (N2, N3; P < 0.0001).
23 patients presented with metastasis at time of
diagnosis, 91.3% of those had diagnosis delay >6 months
(p < 0.0001) after symptoms. Diagnosis delay and asso-
ciated clinical stages of breast cancer at time of diagnosis
are shown in Table 5.
Discussion
Published data from the Middle East and North Africa
(MENA) region suggest lower quality of health care
among patients with cancer than in developed countries
[18]. On other hand, the World Health Organization
predicts an increase in cancer cases in developing coun-
tries. Significant advances in breast cancer management
can probably improve the quality and efficacy of onco-
logy practice in the MENA region [19,20].This study shows the diagnosis delay of breast cancer
is a serious problem in Libya. Through understanding
the causes of delay it may be possible to reduce delays
and to improve early diagnosis.
The average time before medical advice and diagnosis
was long, and the diagnosis time was higher than in
developed or developing countries [21]. Perhaps this
trend can be attributed to low awareness of health issues
among women, to poor information campaigns, and to
the absence of mammographic or other screening pro-
grams for early detection of breast cancer in Libya.
This study showed that there was a relationship bet-
ween the patient- associated factors delayed presentation
of symptoms, in agreement with Ramirez et al. [7].
Patients are more likely to attribute new symptoms to
less serious conditions than to life-threatening diseases
[22]. Studies have reported delays when the patients
assumed that symptoms were benign and would fade
without interference [23].
We also observed that patients often considered symp-
toms as benign. This was the most important reason
for delay in seeking doctors' advice as shown by Arndt
et al. [10].
In current study, 13.0% of the respondents had taken
alternative therapy, compared to 15-73% in Europe [24].
Most patients took alternative treatment as means to
avoid surgery. Some patients believed that there were no
effective treatments for breast cancer, or that traditional
medicines are more effective than modern drugs.
While taking alternative treatments, most patients
experienced worsening of symptoms, which eventually
led to more advanced stage. The patients want to receive
medical therapy but when the response is not favorable,
they often use traditional medicine as the last hope [10].
This study showed that a negative information of
breast cancer treatment caused delays as in Nigeria [25]
and Malaysia [26]. Negative information, such as side-
effects and expected toxicity of chemotherapy led to fear
and refusal of therapy. Some patients believed that the
effects of chemotherapy were worse than breast cancer
itself. Fear of divorce or remarriage of the husband could
lead some women to decide not to get their symptoms
diagnosed if they suspected breast cancer. Some patients
also believed that breast cancer could not be cured [27],
so there was no point of having it diagnosed and treated.
Diagnosis delay was also related to a belief that mastec-
tomy causes disfigurement and disability [28].
There are certain ‘alarm symptoms’, important for cre-
ate cancer diagnosis [29]. However, these are not always
known within doctors or nurses. In the present study,
we found that the respondents were inappropriately
reassured after the first visit to the doctor that a lump
can be considered benign without biopsy. This is a false
attitude. In this study, this attitude was an important
Table 4 Diagnosis delay in Libyan breast cancer by an accordance to socio-economic factors, health behavior and
tumor related factors
Predicting factors Number of
patients
Proportion of patients according to diagnosis time (percent) P value
<3 months 3-6 months >6 months
Age years < 50 133 48.9 18.0 33.1 0.033
≥ 50 67 35.8 11.9 52.2
Age years < 50 133 48.9 18.0 33.1 0.004
50-65 32 53.1 12.5 34.4
≥ 65 35 20.0 11.4 68.6
Current employment status House wife 111 38.7 16.2 45.0 0.09
Employed 89 51.7 15.7 32.6
Education Literate 124 61.6 18.1 20.3 0.009
Illiteracy 76 30.9 15.8 53.3
Menopausal status Pre-menopausal 127 49.6 18.1 32.3 0.054
Pos-menopausal 73 35.6 12.3 52.1
Marital status Married 158 43.7 14.6 41.8 0.648
Single 42 47.6 21.4 31.0
Breast feeding Yes 133 41.4 13.5 45.1 0.09
No 16 62.5 12.5 25.0
Oral contraceptive Yes <5 years 35 45.7 8.6 45.7 0.043
Yes > 5 years 14 14.3 28.6 57.1
No t used 151 47.0 16.6 36.4
Family history Positive 18 55.6 5.6 38.9 0.324
Negative 182 43.4 17.0 39.6
History of benign breast disease Yes 30 26.7 20.0 53.3 0.029
No 170 47.6 15.3 37.1
Breast self examination Yes 9 100.0 0.0 0.0 <0.0001
No 191 41.9 16.8 41.4
Symptoms Lump 136 58.8 16.9 24.3 <0.0001
Others 64 14.1 14.1 71.9
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results were reported by Goodson et al. [16]. Even
through the majority of lumps in young patients are be-
nign, histological or cytological diagnosis should be
available of every lump.
Interestingly, the present study revealed that the initial
breast symptoms that did not include a lump were
strongly associated with diagnosis delay. The discovery
of a breast lump reduces the patient delay as confirmed
in other studies [7,9]. The findings suggest that doctors
and patients need to be educated about the different
types of breast cancer symptoms.
Mammography is a sensitive means for early detection
of breast cancer, but both clinical breast examination
(CBE) and breast self-examination (BSE) have the poten-
tial to advance the diagnosis of breast cancer without
the expense of a mammography facility [30]. Women with
regular breast self-examination tended to seek medicalcare more rapidly and to have earlier stages of disease at
diagnosis [31].
We observed that the patients who made self examin-
ation monthly were more educated, younger and asked
for medical help rapidly than less educated or older
patients.
Many studies have shown that older age is a predictor
of diagnosis delay [7,20,32]. Since older age is a risk fac-
tor for both developing breast cancer and subsequent
delayed presentation, any intervention program should
target older women in particular [33]. In the current
study, older women waited longer than younger women
before presenting their symptoms to a physician.
The value of education on breast cancer symptoms
has been reported in a number of studies [20,34]. Our
findings suggest that lack of knowledge about breast
cancer is an important factor in Libya and there is a
need for public educational programs especially for less
Table 5 Diagnosis delay and risk of late stage breast cancer at time of diagnosis
Tumour characteristics Number of
patients
Proportion of patients according to diagnosis time (percent) P value
<3 months 3-6 months >6 months
Clinical stage Stage 1 18 94.4 5.6 0.0 <0.0001
Stage 2 51 74.5 23.5 2.0
Stage 3 108 2.8 10.2 87.0
Stage 4 23 0.0 0.0 100.0
Clinical stage Early stages 69 79.7 18.8 1.4 <0.0001
Late stages 131 2.3 8.4 89.3
T T 1 25 96.0 4.0 0.0 <0.0001
T 2 54 60.8 33..3 5.9
T 3 78 4.3 25.7 70.0
T 4 43 0.0 4.8 95.2
N N 0 50 80.0 18.0 2.0 <0.0001
N 1 76 22.4 31.6 46.1
N 2 58 1.7 12.1 86.2
N 3 16 0.0 0.0 100.0
M M 0 177 32.8 21..5 45.8 <0.0001
M 1 23 0.0 8.7 91.3
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moral considerations may limit the use of mass media
for publicizing breast cancer awareness.
We observed that women with a history of fibrocystic
disease were significantly associated with delay. The
same results were reported by Arndt et al. [10]. Explan-
ation is that former episodes of breast tissue alterations,
if benign is also later considered as benign by their
doctors.
Thus, it might be worthwhile to encourage women
with known benign breast disease to present new breast
symptoms promptly. Additionally, doctors should under-
stand that new symptoms should be evaluated as poten-
tial new risks for breast cancer.
Similar to recent studies, our findings indicated that
those patients who were diagnosed late had significantly
bigger tumor size and presented with an advanced stage
of the disease. The influence of delay on tumor size and
disease stage is well documented [7,8].
Even through the present study does not provide infor-
mation regarding the distribution of tumor differentia-
tion, it is important to note that a substantial proportion
of late stage diagnosis of poorly differentiated breast can-
cer cases could potentially have been avoided if patients
with breast cancer had seen a doctor earlier [10].
Conclusions
Diagnosis delay is very serious problems in Libya. Diag-
nosis delay was associated with complex interactions bet-
ween social, medical and other patient-associated factorsleading to advanced stages, potentially resulting in a high
mortality. There is a need for improving breast cancer
awareness and training of general practitioners to reduce
breast cancer mortality by promoting early detection. The
treatment guidelines should pay more attention to the
early phases of breast cancer. Especially, guidelines for
good practices in managing detectable of tumors are
necessary.
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